← All trials
NCT03031184
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Dec 1, 2018
- Completion date
- Aug 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 471
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of SussexLead sponsor
- University of East AngliaCollaborator
- University of CambridgeCollaborator
- University of ManchesterCollaborator
- University of LondonCollaborator
- Alzheimer's SocietyCollaborator
- University of SussexOverall official - principal investigator
- University of SussexCollaborator
- Newcastle UniversityCollaborator
- University of BirminghamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.